LSD-assist
57 evidence topics · 4 sources
Objective
Registered objective
Published aim of the primary analysis
“This study aimed to investigate the efficacy and safety of lysergic acid diethylamide (LSD)-assisted therapy in patients who experienced anxiety with or without association with a life-threatening illness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aim of the long-term follow-up
“We investigated the long-term safety and efficacy of lysergic acid diethylamide (LSD)-assisted therapy in patients with anxiety with or without life-threatening illness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We hypothesised effects would not be sustained up to the 12-month follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Role in the development of DT120 (MM-120)
Location and study date
Study identifiers, dates, and status
| Item | Registry record |
|---|---|
| Brief title with acronym | “LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders (LSD-assist)” |
| Other study ID | “BASEC 2016-00992” |
| Phase | “Phase 2” |
| Study start (actual) | “2017-06-23” |
| Primary completion (actual) | “2021-12-15” |
| Study completion (actual) | “2021-12-15” |
| First posted | “2017-05-15” |
| Last update posted | “2021-12-22” |
| Results | “No Results Posted” |
Sites: two centers in Switzerland
“This study has 2 locations” (opens the source at this quote in a new tab)
“Sponsor University Hospital, Basel, Switzerland” (opens the source at this quote in a new tab)
“The study was an investigator-initiated, two-centre trial, with one study centre at the University Hospital Basel, Switzerland, and the other study centre at the Clinic Dr Peter Gasser, Solothurn, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Enrollment period, last visit, and follow-up completion
“Enrolment began on 23 June 2017 and finished on 1 February 2021. The trial ended as planned, with the last patient visit on 15 December 2021. The assessment of follow-up questionnaires was completed by January 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First presentation of results, May 2022
Study design
Official title and registered design
| Design element | Registry record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “Quadruple” |
Two-center, two-period, random-order crossover design
“The study is an investigator-initiated 2-center trial that used a double-blind, placebo-controlled, 2-period, random-order, crossover design with 2 sessions with either oral LSD (200 μg) or placebo per period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment periods, session spacing, and visit schedule
“The order of administration was random and counterbalanced.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After study inclusion, the participants were randomly assigned to LSD or placebo in the first treatment period and vice versa in the second treatment period by order of enrolment and group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As previously reported in detail, the study included a screening visit and two 24-week treatment periods per participant. Each treatment period consisted of two treatment sessions and five study visits. Treatment sessions were separated by 6 weeks (±2 weeks). Study visits were conducted at baseline, between treatment sessions, and 2, 8 and 16 weeks after the second treatment session. The last visit in the second period also served as the end-of-study visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Planned long-term follow-up by mailed questionnaire
“Follow-up questionnaires were sent by mail to all participants (including dropouts) 12 months after the end-of-study visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For those who received LSD in the first period, the follow-up was assessed 94 weeks after the last LSD treatment. For those who received placebo in the first period, the follow-up was assessed 68 weeks after the last LSD treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The follow-up was conducted 12 months after the end-of-study visit by post to investigate the same outcome measures as during the study, in which participants completed questionnaires about long-lasting effects and answered questions about adverse events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Funding, ethics approval, and licensing of the data to the developer of DT120
“The study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization Guidelines in Good Clinical Practice and approved by the Ethics Committee of Northwest Switzerland (EKNZ), Swiss Federal Office for Public Health, and Swissmedic” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was funded by the University Hospital Basel and Swiss Medical Society for Psycholytic Therapy (SAePT). The funders of the study had no role in the study design, data collection, data analysis, data interpretation or writing the report. M.E.L. and P.G. are consultants for Mind Medicine, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Knowhow and data associated with this work and owned by the University Hospital Basel were licensed by Mind Medicine, Inc., which had no role in financing, planning or conducting the present study or the present publication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria
Exclusion criteria
Anxiety disorder diagnoses eligible, including generalized anxiety disorder
“The goal was to include people with anxiety disorders or significant anxiety that was associated with LTI. LTI was defined as any severe somatic disease, such as a diagnosis of cancer or another advanced-stage potentially fatal illness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“criteria for an anxiety disorder, including generalised anxiety disorder, social phobia and panic disorder, as indicated by the Structured Clinical Interview for the DSM-IV (SCID-IV), or have a score ≥40 on the state or trait STAI at study inclusion. Participants without LTI had to meet DSM-IV criteria for at least one anxiety disorder. Thus, in people without LTI, elevated STAI scores were not sufficient for inclusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recruitment
“Participants were recruited through an advertisement that was placed on website homepages of the University Hospital Basel and Swiss Medical Society for Psycholytic Therapy (SAePT) trial registries, or by word of mouth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Registered interventions
Study drug and placebo as described in the follow-up publication
“LSD free base (>99% purity; Lipomed AG, Arlesheim, Switzerland) was administered as an oral solution in units that contained 100 μg LSD in 1 mL of 96% ethanol. Inactive placebo consisted of identical units that were filled with ethanol only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Randomisation and production were performed according to good manufacturing practice (GMP) by a licensed GMP facility (Apotheke Dr Hysek, Biel, Switzerland).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Session setting, duration, and therapist
“After successful screening, each person was assigned for the entire duration of the study to one investigator/therapist who conducted all treatment sessions and study visits. Treatment sessions lasted approximately 12 h, and study visits lasted approximately 1 h. Study visits consisted of talk therapy, followed by an assessment of adverse events, changes in general medication and administration of the questionnaires.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment sessions were conducted in a calm hospital room (University Hospital Basel) or calm practice room (Clinic Dr Peter Gasser). Only one participant and one investigator/therapist were present during the treatment sessions (exceptions of more than one therapist being present were made upon request by the therapist or participant).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Background treatment: LSD given as an add-on
“However, most people had already received some therapy (e.g. anxiolytics, antidepressants or talking psychotherapy) when they entered the trial, and antidepressant treatment was only tapered off for LSD/placebo sessions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LSD therapy therefore served as an add-on for those who had already received treatment at trial inclusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Additional psychedelic sessions after the trial
“Six individuals from the original study continued psychedelic therapy (LSD, 3,4-methylenedioxymethamphetamine (MDMA) or psilocybin) within the Swiss limited-use programme and underwent one to four additional psychedelic sessions (all LSD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using State-Trait anxiety inventory global score as the primary endpoint
Registered primary and secondary outcomes
| Outcome | Quoted registry text |
|---|---|
| Primary | “Reduction in anxiety assessed by questionnaires (STAI) 16 weeks after LSD compared with placebo” |
| Primary time frame | “16 weeks post-intervention” |
| Secondary: depression | “Reduction in depression will be assessed by questionnaires (HDRS, BDI) 2, 8 and 16 weeks after LSD compared with placebo” |
| Secondary: anxiety at earlier visits | “Reduction in anxiety will be assessed by questionnaire (STAI) 2 and 8 weeks after LSD compared with placebo” |
| Secondary: psychopathology | “Reduction of psychopathological symptoms will be assessed by questionnaire (SCL-90) 2, 8, and 16 weeks after LSD compared with placebo” |
| Secondary: sustained response | “Follow-up using different questionnaires to compare (within-subject) the 52-week response with Responses from baseline and 16-weeks.” |
Primary endpoint as published: STAI-Global score at 16 weeks
“The primary end point was anxiety symptoms 16 weeks after the last treatment session, assessed by the Spielberger State-Trait Anxiety Inventory-Global score in 42 patients. Further outcome measures included ratings for depression symptoms (Beck Depression Inventory and Hamilton Depression Rating Scale, 21-item version) and ratings for acute subjective drug effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Purpose of the STAI global score as stated by the sponsor
Response and remission definitions
“The clinical response was defined as a STAI-G reduction ≥ 30%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Remission was defined as score <80 for the STAI-G.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Remission was defined as score <10 for the BDI; only patients with a score of ≥10 at screening were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcome measures of the long-term follow-up
“The primary outcome measure in the present study was defined the STAI-G (with the primary end-point 16 weeks after the last treatment session, as reported previously).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary outcomes that were assessed during the study and at the follow-up were scores on the STAI-State (STAI-S), STAI-Trait (STAI-T), BDI and SCL-90-R.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At follow-up, in addition to the therapeutic outcome questionnaires, a questionnaire about persisting effects of psychedelics was administered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Personality traits at screening and the 1-year follow-up were assessed using the 60-item NEO - Five-Factor Inventory (NEO-FFI)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled: 46 participants
Analyzed in the primary analysis: 42 participants
Analyzed at long-term follow-up
“Follow-up questionnaires were returned by 35 individuals (15 in the group with LTI and 20 without LTI). People who had at least two LSD sessions and one outcome measure were included in the analysis. One person did not complete the STAI questionnaires, resulting in a total of 33 people for all STAI measures and 34 people for all other measures. A total of 39 participants (20 in the LSD-first group and 19 in the placebo-first group) were eligible for the change-from-baseline analysis per treatment group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Primary analysis restricted to the first period because of carryover
Follow-up analysis set and statistical model
“People who had at least two LSD sessions and one outcome measure were included in the analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Outcomes were analysed using Linear Mixed Effects models, employing the lme4 and lmer test packages in R. Time points were used as the fixed factor, and participants were used as the random factor. For therapeutic outcomes but not personality traits, baseline values of the periods were considered covariates (change from baseline values for the respective period).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tukey's post hoc pairwise comparisons of least square means across time points were performed to elucidate significant differences between baseline and follow-up. These analyses were planned and hypothesised a priori in the protocol.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exploratory associations between the acute response to LSD and main follow-up outcome measures were assessed using Pearson's correlations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The criterion for significance was P < 0.05.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Enrolled and analyzed in the primary analysis
Participants contributing data at long-term follow-up
“Detailed data on dropouts during the study were previously reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Follow-up questionnaires were returned by 35 individuals (15 in the group with LTI and 20 without LTI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We received written feedback from 18 participants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Duration of anxiety and prior treatment
“On average, people were diagnosed with anxiety 10 ± 9 years (mean ± s.d.) prior to study inclusion (range: 0–39 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many of the participants in the present trial had a long history of treatment attempts/failures and were to some degree non-responsive chronic cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Imbalance in symptom ratings between sequence groups
Personality trait openness at study inclusion
Efficacy results
Primary endpoint: STAI-Global change at 16 weeks (between-subjects analysis)
“LSD treatment resulted in significant reductions of State-Trait Anxiety Inventory-Global scores up to 16 weeks after treatment (least-square mean [standard error] change from baseline difference = -16.2 [5.8], 95% CI, -27.8 to -4.5, d = -1.18, p = .007).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Depression: HAM-D-21 and BDI
“Similar effects were observed for ratings of comorbid depression on the Hamilton Depression Rating Scale, 21-item version (-7.0 [1.9], 95% CI, -10.8 to -3.2, d = -1.1, p = .0004) and the Beck Depression Inventory (-6.1 [2.6], 95% CI, -11.4 to -0.9, d = -0.72, p = .02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
STAI-G response and time course reported at the oral presentation
Follow-up at 12 months after the end-of-study visit: STAI-G change from baseline
“Participants reported a sustained reduction of STAI-G scores compared with baseline (least square means (95% CI) = −21.6 (−32.7, −10.4), d = 1.04, P < 0.001, for those who received LSD in the first period (94 weeks after the last LSD treatment) and −16.5 (−26.2, −6.8), d = 1.02, P < 0.05, for those who received LSD in the second period (68 weeks after the last LSD treatment)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The LSD-first group improved significantly on the STAI-G compared with the primary end-point (16 weeks after last drug administration) at follow-up. The least square mean (95% CI) change was −9.7 (−15.5, −4.0), while the placebo-first group showed no further improvement: 1.2 (−4.2, 6.6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Follow-up at 12 months: depression
“Similar effects were observed for comorbid depression with change from baseline BDI scores of −8.1 (−13.2, −3.1), d = 0.71, P < 0.01, and −8.9 (−12.9, −4.9), d = 1.21, P < 0.01, for the LSD-first and placebo-first groups, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Follow-up at 12 months: remission and response
“At follow-up, a total of 11 participants (33%) were in remission with regard to anxiety symptoms, and a total of 17 participants (49%) were in remission with regard to depression symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subgroups: life-threatening illness, further psychedelic therapy, and generalized anxiety disorder
“Post hoc tests revealed no significant differences between people with and without LTI (P = 0.45 for the LSD-first group and P = 0.41 for the placebo-first group), people whose therapy was continued within the Swiss limited-use programme (P = 0.89 for the LSD-first group and P = 0.66 for the placebo-first group) and people with a formal diagnosis of generalised anxiety disorder (GAD; P = 0.35 for the LSD-first group and P = 0.65 for the placebo-first group).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The present study included participants with a range of anxiety diagnoses that were included based on their symptom severity; this approach is supported by the findings that we found no difference in response between the groups (LTI versus non-LTI) and diagnosis (GAD versus non-GAD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Persisting Effects Questionnaire at follow-up
“On the PEQ, high ratings of positive attitudes about life and/or self, positive mood changes, altruistic/positive social effects and positive behavioural changes were reported (all >47% of the total maximum score), whereas ratings of the negative counterparts remained low (all <10% of the total maximum score).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On average, people rated the experience as ‘among the ten most personally meaningful experiences in life’, as ‘very much’ spiritually meaningful and as having positively influenced their sense of well-being or life satisfaction” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
General psychiatric symptoms (SCL-90-R)
Written participant feedback at follow-up
“We received written feedback from 18 participants, which included the following topics: therapeutic potential of LSD (14 participants; 13 positive, one negative), setting and atmosphere (five participants; three positive, two negative), guide/therapist interaction (two participants; one positive, one negative), dose-related feedback (two participants; both negative (one participant reported the dose was too high, and one participant reported the dose was too low)), post-session effects (two participants; one positive, one negative) and comparison between dosing days (one participant; negative).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Acute untoward effects and treatment-related serious adverse event
Serious adverse event description and suicidality
Long-term safety: flashbacks and hallucinogen persisting perception disorder
“Additionally, the follow-up questionnaire included questions about adverse effects, including flashbacks and hallucinogen persisting perception disorder (HPPD; see Supplemental Information for detailed questions)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No additional adverse events were reported in the follow-up period, and no additional clinically relevant flashback phenomena or HPPD occurred.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LSD did not induce any long-term adverse events, such as flashbacks or HPPD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lasting negative effects were minimal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
NCT03153579 was an investigator-initiated phase 2 crossover trial at two centers in Switzerland (University Hospital Basel and a private practice in Solothurn), funded by University Hospital Basel and the Swiss Medical Society for Psycholytic Therapy. The registered summary planned 40 participants; 46 were enrolled, and 42 were included in the primary analysis. Because of carryover effects, the primary results are a between-subjects comparison of the first period, in which a STAI-G response (reduction of 30% or more) was reported for 13 of 20 participants (65%) receiving LSD and 2 of 22 (9%) receiving placebo. The response figures come from the May 2022 company announcement of an oral presentation; the primary publication reports the least-squares mean difference of -16.2 points (95% CI, -27.8 to -4.5) at 16 weeks.
The population combined participants with an anxiety disorder and participants with anxiety associated with a life-threatening illness, for whom a STAI score of 40 or more could substitute for a DSM-IV diagnosis; eligible diagnoses included generalized anxiety disorder, social phobia, and panic disorder, and the follow-up post hoc tests found no difference in STAI-G change between participants with and without a formal GAD diagnosis (P = 0.35 and P = 0.65). The primary endpoint was a self-reported questionnaire, and the follow-up authors state that no objective, interview-based data and no measure of expectancy were collected. The placebo-first group had higher symptom ratings at inclusion, a difference that remained throughout the trial.
Each participant received LSD 200 μg in two sessions of approximately 12 hours with one investigator or therapist, and study visits included talk therapy. The follow-up publication describes the study drug as LSD free base in an oral solution of 96% ethanol (100 μg per mL) with an ethanol-only placebo, while the registry describes placebo capsules containing mannitol. Most participants had received anxiolytics, antidepressants, or psychotherapy before entry, antidepressants were tapered only for the sessions, and the authors state that LSD served as an add-on treatment; the participants were described as having a long history of treatment attempts and failures, with anxiety diagnosed a mean of 10 years before inclusion.
The 12-month follow-up had no control group, since all participants had received LSD by then. Questionnaires were returned by mail by 35 participants, with 33 contributing STAI measures, and 6 participants continued psychedelic therapy in the Swiss limited-use programme with one to four additional LSD sessions. The authors state that it is largely unclear what therapy participants received between the end-of-study visit and follow-up. The primary publication reports transient, mild acute untoward effects in 8 participants (19%) and one treatment-related serious adverse event of acute transient anxiety (2%), which the company announcement describes as acute transient anxiety and delusions. The registry has no posted results.
Two authors are consultants for Mind Medicine, Inc., which licensed the knowhow and data owned by University Hospital Basel; the authors state that the company had no role in financing, planning, or conducting the follow-up study, and the company states that it has exclusive access and rights to the data.
Limitations stated by the authors of the follow-up
“The present study also has limitations. The present analysis included no control group for long-term effects of LSD. Additionally, no objective, interview-based data were collected, the herein-reported data are based on self-report questionnaires and no measure of expectancy was collected. All participants received LSD within this crossover study. Lasting effects were compared with measures before LSD-assisted therapy over time and within subjects. Therefore, we cannot exclude the possibility that other factors contributed to the long-term effects. Furthermore, it is largely unclear what therapy people received between the end-of-study visit and the follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment expectancy and differences between sequence groups
“However, it remains unclear why individuals in the LSD-first group appeared to benefit more from LSD-assisted therapy compared with those who received placebo first.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This also raises a question about treatment expectancy and whether people in the placebo-first group felt disadvantaged by not receiving LSD in the first period and whether this motive remained intact and influenced the subsequent therapeutic response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Also, the two placebo sessions in the second period could have served as additional integration sessions in those who received LSD in the first period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Additional sessions outside the trial
“There was no significant difference in the primary treatment outcome (STAI-G) at follow-up compared with those who had no further psychedelic-assisted therapy, although an important consideration is the small sample size (n = 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote